A Philadelphia trial judge overseeing mass tort litigation involving the digestive drug Reglan on Friday denied a bid by generic manufacturers to dismiss claims against them in roughly 2,000 lawsuits on the basis of a recent U.S. Supreme Court decision.
Philadelphia Common Pleas Court Judge Sandra Mazer Moss overruled without prejudice preliminary objections by generic companies that had argued that under the Supreme Court’s decision Pliva v. Mensing , state claims against them for failing to warn about the risks of taking the drug were pre-empted by federal regulations.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
